BTL has established a dedicated laser division and introduced EXOLASE ONE, positioned as the first fused erbium laser combining two erbium wavelengths in a single handpiece. The device targets ablative and fractional resurfacing across face and body, competing directly against Cutera's Lasemdx and Cynosure's platforms in the high-end ablative market.
Fused-wavelength architecture allows practitioners to toggle between wavelengths without swapping handpieces, reducing procedure time and simplifying workflow. Erbium lasers remain the gold standard for ablative resurfacing—superior hemostasis and collagen remodeling versus CO2—but the market has consolidated around a handful of players. BTL's entry signals that device manufacturers see margin opportunity in premium resurfacing platforms, particularly as practices seek to differentiate full-body treatments beyond injectables and radiofrequency.